Retrospective multicenter matched case–control study on the risk factors for narcolepsy with special focus on vaccinations (including pandemic influenza vaccination) and infections in Germany

Sleep Medicine

Volumn 34, Issue , 2017, Pages 71-83

  Oberle, Doris ^a   Pavel, Jutta ^a   Mayer, Geert ^b   Geisler, Peter ^c   Keller Stanislawski, Brigitte ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

^b Hephata Klinik   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Germany; Narcolepsy; Pandemic influenza A H1N1 v vaccine; Risk factors

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; ARTICLE; BIRTH; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DEMOGRAPHY; FEMALE; GENDER; GERMANY; HEALTH CENTER; HUMAN; INFANT; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NARCOLEPSY; PANDEMIC INFLUENZA; RETROSPECTIVE STUDY; RISK FACTOR; AGED; CLINICAL TRIAL; INFECTION; INFECTION CONTROL; MIDDLE AGED; ODDS RATIO; PRESCHOOL CHILD; STATISTICAL MODEL; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GERMANY; HUMANS; INFECTION; INFECTION CONTROL; LOGISTIC MODELS; MALE; MIDDLE AGED; NARCOLEPSY; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS; VACCINATION; YOUNG ADULT;

EID: 85017193283     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2017.02.026     Document Type: Article

References (47)

1. [1] Leschziner, G., Narcolepsy: a clinical review. Pract Neurol 14 (2014), 323–331.
2. [2] Peyron, C., Faraco, J., Rogers, W., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6 (2000), 991–997.
3. [3] Thannickal, T.C., Moore, R.Y., Nienhuis, R., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27 (2000), 469–474.
4. [4] Thannickal, T.C., Nienhuis, R., Siegel, J.M., Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep 32 (2009), 993–998.
5. [5] Savvidou, A., Knudsen, S., Olsson-Engman, M., et al. Hypocretin deficiency develops during onset of human narcolepsy with cataplexy. Sleep 36 (2013), 147–148.
6. [6] Mignot, E., Young, T., Lin, L., et al. Nocturnal sleep and daytime sleepiness in normal subjects with HLA-DQB1*0602. Sleep 22 (1999), 347–352.
7. [7] Poirier, G., Montplaisir, J., Decary, F., et al. HLA antigens in narcolepsy and idiopathic central nervous system hypersomnolence. Sleep 9 (1986), 153–158.
8. [8] Guilleminault, C., Partinen, M., Quera-Salva, M.A., et al. Determinants of daytime sleepiness in obstructive sleep apnea. Chest 94 (1988), 32–37.
9. [9] Mignot, E., Lin, X., Arrigoni, J., et al. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep 17:8 Suppl. (1994), S60–S67.
10. [10] Kawashima, M., Tamiya, G., Oka, A., et al. Genomewide association analysis of human narcolepsy and a new resistance gene. Am J Hum Genet 79 (2006), 252–263.
11. [11] Deloumeau, A., Bayard, S., Coquerel, Q., et al. Increased immune complexes of hypocretin autoantibodies in narcolepsy. Plos One, 5, 2010, e13320.
12. [12] Cvetkovic-Lopes, V., Bayer, L., Dorsaz, S., et al. Elevated tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Investig 120 (2010), 713–719.
13. [13] Hallmayer, J., Faraco, J., Lin, L., et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 41 (2009), 708–711.
14. [14] Mahlios, J., De la Herrán-Arita, Alberto K., Mignot, E., et al. The autoimmune basis of narcolepsy. Curr Opin Neurobiol 23 (2013), 767–773.
15. [15] Aran, A., Lin, L., Nevsimalova, S., et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 32 (2009), 979–983.
16. [16] Partinen, M., Saarenpaa-Heikkila, O., Ilveskoski, I., et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. Plos One, 7, 2012, e33723.
17. [17] Nohynek, H., Jokinen, J., Partinen, M., et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. Plos One, 7, 2012, e33536.
18. [18] Wijnans, L., Lecomte, C., de Vries, C., et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 31 (2012), 1246–1254.
19. [19] Szakacs, A., Darin, N., Hallbook, T., Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology 80 (2013), 1315–1321.
20. [20] Dauvilliers, Y., Arnulf, I., Lecendreux, M., et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain 136 (2013), 2486–2496.
21. [21] Heier, M.S., Gautvik, K.M., Wannag, E., et al. Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Med 14 (2013), 867–871.
22. [22] Miller, E., Andrews, N., Stellitano, L., et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ, 346, 2013, f794.
23. [23] Stowe, J., Miller, E., Andrews, N., et al. Risk of narcolepsy after AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine in adults: a case-coverage study in England. Sleep 39 (2016), 1051–1057.
24. [24] Montplaisir, J., Petit, D., Quinn, M.-J., et al. Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec. Plos One, 9, 2014, e108489.
25. [25] O'Flanagan, D., Barret, A.S., Foley, M., et al. Investigation of an association between onset of narcolepsy and vaccination with pandemic influenza vaccine, Ireland April 2009-December 2010. Euro Surveill 19 (2014), 15–25.
26. [26] Persson, I., Granath, F., Askling, J., et al. Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up. J Intern Med 275 (2014), 172–190.
27. [27] Ahmed, S.S., Schur, P.H., MacDonald, N.E., et al. 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun 50 (2014), 1–11.
28. [28] Ahmed, S.S., Volkmuth, W., Duca, J., et al. Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Sci Transl Med, 7, 2015, 294.
29. [29] Arango, M.-T., Kivity, S., Shoenfeld, Y., Is narcolepsy a classical autoimmune disease?. Pharmacol Res 92 (2015), 6–12.
30. [30] Ahmed, S.S., Steinman, L., Mechanistic insights into influenza vaccine-associated narcolepsy. Hum Vaccines Immunother 12 (2016), 3196–3201.
31. [31] Walter, D., Böhmer, M.M., an der Heiden, M., et al. Monitoring pandemic influenza A(H1N1) vaccination coverage in Germany 2009/10-results from thirteen consecutive cross-sectional surveys. Vaccine 29 (2011), 4008–4012.
32. [32] Oberle, D., Drechsel-Bäuerle, U., Schmidtmann, I., et al. Incidence of narcolepsy in Germany. Sleep 38 (2015), 1619–1628.
33. [33] Drake, C., Nickel, C., Burduvali, E., et al. The pediatric daytime sleepiness scale (PDSS): sleep habits and school outcomes in middle-school children. Sleep 26 (2003), 455–458.
34. [34] Poli, F., Overeem, S., Lammers, G.J., et al. Narcolepsy as an adverse event following immunization: case definition and guidelines for data collection, analysis and presentation. Vaccine 31 (2012), 994–1007.
35. [35] Aldrich, M., Chervin, R., Malow, B., Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. Sleep 20 (1997), 620–629.
36. [36] Deutsche Gesellschaft für Neurologie, AWMF-Leitlinien-register Nr. 030/056: Narkolepsie. 2012 Available at: http://www.awmf.org/leitlinien/detail/ll/030-056.html [Accessed 25 August 2016].
37. [37] THL Press Release, Increased risk of narcolepsy observed also among adults vaccinated with Pandemrix in Finland. 2013 Available at: https://www.thl.fi/en/web/thlfi-en/whats-new/press-releases-and-news/press-release/-/asset_publisher/dwJikhRa3Ejc/content/increased-risk-of-narcolepsy-observed-also-among-adults-vaccinated-with-pandemrix-in-finland [Accessed 23 May 2013].
38. [38] Partinen, M., Kornum, B.R., Plazzi, G., et al. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol 13 (2014), 600–613.
39. [39] Vaarala, O., Vuorela, A., Partinen, M., et al. Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for Pandemrix-associated narcolepsy risk. Plos One, 9, 2014, e114361.
40. [40] Hidalgo, H., Kallweit, U., Mathis, J., et al. Post tick-borne encephalitis virus vaccination narcolepsy with cataplexy. Sleep 39 (2016), 1811–1814.
41. [41] Krahn, L.E., Martin, K.A., Silber, M.H., Narcoleptic patients’ perceptions of nicotine. J Clin Sleep Med, 5, 2009, 390.
42. [42] Kotagal, S., Krahn, L.E., Slocumb, N., A putative link between childhood narcolepsy and obesity. Sleep Med 5 (2004), 147–150.
43. [43] Plazzi, G., Moghadam, K.K., Maggi, L.S., et al. Autonomic disturbances in narcolepsy. Sleep Med Rev 15 (2011), 187–196.
44. [44] Winstone, A.M., Stellitano, L., Verity, C., et al. Clinical features of narcolepsy in children vaccinated with AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine in England. Dev Med Child Neurol 56 (2014), 1117–1123.
45. [45] Han, F., Lin, L., Warby, S.C., et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 70 (2011), 410–417.
46. [46] Melén, K., Partinen, M., Tynell, J., et al. No serological evidence of influenza A H1N1pdm09 virus infection as a contributing factor in childhood narcolepsy after Pandemrix vaccination campaign in Finland. Plos One, 8, 2013, e68402.
47. [47] Wijnans, L., Dodd, C., de Ridder, M., et al. Pandemic influenza vaccine and narcolepsy: simulations on the potential impact of bias. Expert Rev Vaccines 15 (2016), 573–584.